The Erlotinib Hydrochloride market is poised for steady expansion over the next decade as the global oncology landscape continues to evolve. Erlotinib hydrochloride, a targeted epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has played a significant role in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. With the rising prevalence of cancer...